USANA Health Sciences, Inc. (NYSE:USNA) Insider Sells $240,489.08 in Stock

USANA Health Sciences, Inc. (NYSE:USNA) insider Paul A. Jones sold 6,266 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total transaction of $240,489.08. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

USANA Health Sciences Stock Up 0.9 %

USNA stock opened at $39.48 on Friday. The company’s 50-day moving average price is $43.95 and its two-hundred day moving average price is $46.15. USANA Health Sciences, Inc. has a 12 month low of $37.35 and a 12 month high of $65.27. The firm has a market cap of $752.00 million, a P/E ratio of 12.30, a P/E/G ratio of 1.28 and a beta of 0.90.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, July 23rd. The company reported $0.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.11). USANA Health Sciences had a net margin of 6.29% and a return on equity of 11.13%. The firm had revenue of $212.87 million during the quarter, compared to the consensus estimate of $218.64 million. During the same period last year, the business earned $0.89 earnings per share. Equities analysts predict that USANA Health Sciences, Inc. will post 2.5 EPS for the current year.

Institutional Trading of USANA Health Sciences

Several institutional investors and hedge funds have recently modified their holdings of USNA. Quest Partners LLC bought a new position in USANA Health Sciences in the 4th quarter valued at approximately $66,000. CWM LLC increased its holdings in shares of USANA Health Sciences by 49.6% during the fourth quarter. CWM LLC now owns 1,267 shares of the company’s stock worth $68,000 after buying an additional 420 shares in the last quarter. BOKF NA lifted its stake in shares of USANA Health Sciences by 274.5% in the 1st quarter. BOKF NA now owns 2,771 shares of the company’s stock valued at $133,000 after acquiring an additional 2,031 shares during the last quarter. Trexquant Investment LP acquired a new stake in shares of USANA Health Sciences during the 4th quarter valued at $266,000. Finally, Price T Rowe Associates Inc. MD grew its position in USANA Health Sciences by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company’s stock worth $284,000 after acquiring an additional 494 shares during the last quarter. 54.25% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

USNA has been the topic of a number of analyst reports. DA Davidson reduced their price target on USANA Health Sciences from $46.00 to $38.00 and set a “neutral” rating on the stock in a research report on Thursday, July 25th. StockNews.com downgraded USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 24th.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.